New Guidelines Recommend Protein Intake and Strength Training for Ozempic/Mounjaro Users
A new international consensus, published in The Lancet Diabetes & Endocrinology, offers updated guidance for individuals using weight-loss medications like Ozempic, Wegovy, and Mounjaro. These drugs, which target GLP-1 agonists, can lead to muscle mass loss alongside fat reduction. Therefore, the consensus now emphasizes that muscle mass preservation is crucial for successful and healthy treatment outcomes, moving beyond mere weight reduction on the scale.
The guidelines recommend a daily protein intake of 1 to 1.5 grams per kilogram of adjusted body weight, with a minimum of 60 grams spread throughout the day. This is particularly important because reduced appetite, a common side effect, can lead to insufficient protein consumption when it's most needed. When dietary intake falls short, protein supplements may be considered after individual medical evaluation.
Furthermore, the consensus elevates strength training, such as weightlifting, to a central component of the treatment plan, rather than a secondary recommendation. This focus on resistance exercise is intended to stimulate muscle production and counteract muscle loss. The decision to continue, adjust, or pause these medications should be a shared one between doctor and patient, considering factors like persistent nausea, dehydration, rapid weight loss, insufficient nutrient intake, and signs of malnutrition. A prolonged intake below 800 calories daily also warrants careful reevaluation.
This consensus reflects a growing understanding of the complex physiological impacts of potent weight-loss medications. By integrating specific protein targets and mandating strength training, the guidelines acknowledge that sustainable health outcomes require a holistic approach beyond simple caloric deficit. This shift from a purely weight-centric metric to one emphasizing body composition and functional capacity is critical. It addresses potential long-term health risks associated with muscle atrophy, such as reduced metabolic rate and increased frailty, particularly in aging populations. The emphasis on shared decision-making regarding treatment duration also highlights the need for personalized care, recognizing that optimal outcomes and risks vary significantly among individuals.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.